NSJ Bioreagents

CD79a Antibody

Product Code:
 
NSJ-V4633SAF
Product Group:
 
Primary Antibodies
Supplier:
 
NSJ Bioreagents
Host Type:
 
Mouse
Antibody Isotype:
 
Mouse IgG1, kappa
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
rIGA/6986
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Storage:
 
Aliquot the CD79a antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
1 / 2
Western blot testing of human Daudi cell lysate with CD79a antibody (clone rIGA/6986). Expected molecular weight: 25-47 kDa depending on glycosylation level.~
2 / 2
IHC staining of FFPE human tonsil tissue with CD79a antibody (clone rIGA/6986).

Western blot testing of human Daudi cell lysate with CD79a antibody (clone rIGA/6986). Expected molecular weight: 25-47 kDa depending on glycosylation level.~
IHC staining of FFPE human tonsil tissue with CD79a antibody (clone rIGA/6986).

No additional charges, what you see is what you pay! *

CodeSizePrice
NSJ-V4633SAF-100UG100 ug£534.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Application Details:
Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Description:
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with RituximAb (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Format:
Purified
Formulation:
1 mg/ml in 1X PBS; BSA free, sodium azide free
Immunogen:
A recombinant partial protein sequence (within amino acids 1-100) from the human protein was used as the immunogen for the CD79a antibody.
Limitation:
This CD79a antibody is available for research use only.
Localization:
Cell Surface
Purity:
Protein A/G affinity
Uniprot #:
P11912

Documents